Reports Q1 revenue $9.8M, consensus $9.78M. CEO Phillip Chan stated, “We are pleased to announce a strong start to 2024, driven by significant sales growth and operational efficiencies. Q1 2024 product sales were $9.0M, marking the highest quarter for core CytoSorb sales in nearly 3 years. We expanded our product gross margins to 76%, exclusive of a non-recurring inventory adjustment, up an absolute 8% from Q1 2023, which we believe highlights the scalability and efficiency of our state-of-the-art manufacturing facility and processes”.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTSO:
- CytoSorbents Reports First Quarter 2024 Results
- CytoSorbents to hold virutal analyst and investor day
- CytoSorbents to host KOL, Analyst-Investor Day
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting